BioCryst Pharmaceuticals, Inc. revealed that the compensation committee of its board of directors has provided nine incoming employees with stock options to acquire a total of 33,950 shares, alongside restricted stock units (RSUs) for a total of 91,750 shares of BioCryst common stock. This grant, given on July 1, 2026, was deemed essential to attract these new employees. The allocation of options and RSUs adhered to Nasdaq Listing Rule 5635(c)(4).